RXi Completes Enrollment in Phase I Anti-Scarring Drug Trial
September 27, 2012
RXi Completes Enrollment in Phase I Anti-Scarring Drug Trial
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Following Private Placement, RXi Has Funds to Last into 2015
April 4, 2013 / Gene Silencing News - RXi Releases Blinded Phase I Data Hinting at Efficacy of Anti-Scarring Drug, On Track for Phase II
February 21, 2013 / Gene Silencing News - RXi Begins Second Phase I Trial of Anti-Scarring Drug
December 6, 2012 / Gene Silencing News - RXi Releases Positive Safety Data on Scarring Drug, Posts Higher Q3 Loss on Dividend
November 15, 2012 / Gene Silencing News - RXi Begins Phase I Trial of Anti-Scarring Drug Candidate
June 28, 2012 / Gene Silencing News